My NCBI | Sign In
RSS Settings
  • Search: Maggiolo Franco[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 43

    1.

    Efavirenz: a decade of clinical experience in the treatment of HIV.

    Maggiolo F.

    J Antimicrob Chemother. 2009 Nov;64(5):910-28. Epub 2009 Sep 18.PMID: 19767318 [PubMed - in process]Related articlesFree article

    2.

    Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

    Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group.

    J Antimicrob Chemother. 2009 Sep;64(3):616-24. Epub 2009 Jul 19.PMID: 19620134 [PubMed - indexed for MEDLINE]Related articles

    3.

    Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.

    Saracino A, Monno L, Tartaglia A, Tinelli C, Seminari E, Maggiolo F, Bonora S, Rusconi S, Micheli V, Lo Caputo S, Lazzaroni L, Ferrara S, Ladisa N, Nasta P, Parruti G, Bellagamba R, Forbici F, Angarano G.

    Curr HIV Res. 2009 Jul;7(4):425-33.PMID: 19601778 [PubMed - indexed for MEDLINE]Related articles

    4.

    Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.

    d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group.

    Clin Infect Dis. 2009 Aug 15;49(4):612-22.PMID: 19591597 [PubMed - indexed for MEDLINE]Related articles

    5.

    Increasing clinical virulence in two decades of the Italian HIV epidemic.

    Müller V, Maggiolo F, Suter F, Ladisa N, De Luca A, Antinori A, Sighinolfi L, Quiros-Roldan E, Carosi G, Torti C.

    PLoS Pathog. 2009 May;5(5):e1000454. Epub 2009 May 29.PMID: 19478880 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.

    Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F.

    Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. Epub 2009 Jan 5.PMID: 19124665 [PubMed - indexed for MEDLINE]Related articles

    7.

    CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.

    Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, Gregis G, Quinzan G, Ripamonti D, Ravasio V, Suter F.

    AIDS. 2009 Apr 27;23(7):799-807.PMID: 19114869 [PubMed - indexed for MEDLINE]Related articles

    8.

    Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.

    Ripamonti D, Maggiolo F.

    Curr Opin Investig Drugs. 2008 Aug;9(8):899-912. Review.PMID: 18666038 [PubMed - indexed for MEDLINE]Related articles

    9.

    Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection.

    Cattaneo D, Maggiolo F, Ripamonti D, Perico N.

    J Chromatogr Sci. 2008 Jul;46(6):485-9.PMID: 18647467 [PubMed - indexed for MEDLINE]Related articles

    10.

    Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.

    Antinori A, Trotta MP, Lorenzini P, Torti C, Gianotti N, Maggiolo F, Ceccherini-Silberstein F, Nasto P, Castagna A, De Luca A, Mussini C, Andreoni M, Perno CF; GNOMO Study Group.

    Antivir Ther. 2007;12(8):1175-83.PMID: 18240858 [PubMed - indexed for MEDLINE]Related articles

    11.

    Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

    Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

    AIDS. 2007 Nov 30;21(18):2409-15.PMID: 18025877 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.

    Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, Bombana E, Suter F.

    HIV Clin Trials. 2007 Sep-Oct;8(5):282-92.PMID: 17956829 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

    Antivir Ther. 2007;12(6):941-7.PMID: 17926648 [PubMed - indexed for MEDLINE]Related articles

    14.

    Predictors of AIDS-defining events among advanced naïve patients after HAART.

    Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Pietro MD, Migliorino G, Quiros-Roldan E, Ladisa N, Sighinolfi L, Gatti F, Carosi G; Italian MASTER Cohort.

    HIV Clin Trials. 2007 May-Jun;8(3):112-20.PMID: 17621458 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance.

    Maggiolo F, Airoldi M, Callegaro A, Ripamonti D, Gregis G, Quinzan G, Bombana E, Ravasio V, Suter F.

    J Int Assoc Physicians AIDS Care (Chic Ill). 2007 Jun;6(2):87-93.PMID: 17537998 [PubMed - in process]Related articles

    16.

    Efavirenz.

    Maggiolo F.

    Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. Review.PMID: 17516877 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.

    Maserati R, Foli A, Tomasoni L, Sighinolfi L, Maggiolo F, Sacchini D, Di Pietro M, Bertelli D, Tinelli C, Lori F.

    Curr HIV Res. 2007 May;5(3):337-43.PMID: 17504175 [PubMed - indexed for MEDLINE]Related articles

    18.

    Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.

    Ripamonti D, Maggiolo F, Suter F.

    AIDS. 2007 May 11;21(8):1059-60. No abstract available. PMID: 17457107 [PubMed - indexed for MEDLINE]Related articles

    19.

    CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

    Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

    J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.PMID: 17434879 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort.

    Maggiolo F, Ripamonti D, Airoldi M, Callegaro A, Arici C, Ravasio V, Bombana E, Goglio A, Suter F.

    HIV Clin Trials. 2007 Jan-Feb;8(1):9-18.PMID: 17434844 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    2 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity